Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass

This study has been completed.
Information provided by (Responsible Party):
Mark C. Wesley, Children's Hospital Boston Identifier:
First received: January 8, 2010
Last updated: July 29, 2015
Last verified: June 2011
The purpose of this study is to measure blood levels of TXA in children having cardiac surgery which requires cardiopulmonary bypass. TXA is used to reduce bleeding during surgery. This study will help determine if the current dosing of TXA results in therapeutic blood levels.

Congenital Heart Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass

Resource links provided by NLM:

Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:
  • Determine TXA blood levels in children having cardiac surgery with cardiopulmonary bypass. The current dosing recommendations will be utilized. [ Time Frame: multiple times thoughout surgery ] [ Designated as safety issue: No ]

Enrollment: 55
Study Start Date: January 2010
Study Completion Date: December 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
children less than 2 months old
children 2 months to 12 months old
Children > 2 months old and less than or equal to 20 kg


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Children with congenital heart defects having cardiac surgery requiring cardiopulmonary bypass

Inclusion Criteria:

  • congenital heart disease requiring surgical repair with cardiopulmonary bypass

Exclusion Criteria:

  • children weighing over 20 kg
  • family does not want to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01045356

United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Children's Hospital Boston
  More Information

Responsible Party: Mark C. Wesley, MD, Children's Hospital Boston Identifier: NCT01045356     History of Changes
Other Study ID Numbers: x10-01-0006 
Study First Received: January 8, 2010
Last Updated: July 29, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Heart Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on April 27, 2016